Global Digital Pathology Market By Product, By End Use, By Application, By Region, Industry Analysis and Forecast, 2020 - 2026
- February 2021 •
- 220 pages •
- Report ID: 6046673 •
- Format: PDF
The Global Digital Pathology Market size is expected to reach $1.4 billion by 2026, rising at a market growth of 6.2% CAGR during the forecast period. Digital Pathology refers to the image-based information setting which uses computer technology to enable the management of information extracted through a digital slide. The introduction of digital pathology enabled the automation of tests at the time of disease diagnosis across other applications. For example, earlier, five instruments were used to carry out a test by the pathologists but now one digital instrument is enough to carry those tests. Digital pathology solutions deliver high-resolution sample scanning, diagnosis & analysis of images on a computer, storing digital slides on online spaces, that helps pathologists to cross-examine slides by eliminating the need for physical evidences.
The convenience of virtual transportation of slides, the cost-effectiveness of digital pathology products, and better efficiency of digital pathology systems are among the main factors that will fuel the growth of the global digital pathology market. Moreover, the increasing adoption of digital pathology in comparison to conventional pathology diagnosis propels the market growth. Though, the lack of skilled professionals, uncertain reimbursement policies, and hesitation of older generation pathologists to accept the latest technology will restrict the growth of the digital pathology market. However, the market will witness new avenues of growth due to the increasing number of initiatives for commercializing cost-effective digital pathology systems.
Based on Product, the market is segmented into Device, Software and Storage System. By product, the device category procured the major share of the digital pathology market. These devices involve slide management systems and scanners. The main driving factor of the growth of the segment is the increasing academic research activities & improved resolution. These technical improvements like enhancement in magnification & scanning of slides at the Z-axis, provided by whole sliding imaging, are anticipated to create profitable growth opportunities during the forecast period.
End Use Outlook
Based on End Use, the market is segmented into Hospitals, Diagnostic Labs, Biotech & pharma companies and Academic & research institutes. The biotech and pharma companies’ market segment would display sustained growth during the forecast period. It is due to the rising usage of digital pathology in drug development, preclinical GLP pathology, and oncology clinical trials. The growing rates of cancer & the rising demand for advance treatment choice are expected to boost the market growth during the forecast period.
Based on Application, the market is segmented into Drug Discovery & Development, Disease Diagnosis and Academic research. The disease diagnosis market segment would show promising CAGR during the forecast period, owing to the rising rate of chronic diseases & increasing focus of the manufacturers on developing advanced diagnostic techniques. Digital technologies aid in enhancing every phase of diagnosis & make it easy to share all the information across inter or intra-departments.
Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. Based on the region, North America emerged as a dominating region of the digital pathology market by acquiring the largest share in the revenue. This dominance may continue due to the increasing investments in R&D, favorable government initiatives regarding the development of technologically improved systems, increasing adoption of digital imaging, and the presence of major players in this region. Rising usage of digital pathology for diagnosing diseases along with supportive reimbursement policies in the U.S., enhanced quality of cancer diagnosis, is estimated to propel the growth of the market in this region.
The major strategies followed by the market participants are Product Launches and Partnerships. Based on the Analysis presented in the Cardinal matrix; F. Hoffmann-La Roche Ltd. is the major forerunner in the Digital Pathology Market. Companies such as Danaher Corporation, Koninklijke Philips N.V., Inspirata, Inc., and Visiopharm A/S, Mikroscan Technologies, Inc. are some of the key innovators in the market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Danaher Corporation (Leica Biosystems), Koninklijke Philips N.V., Olympus Corporation, F. Hoffmann-La Roche Ltd., ContextVision AB, Hamamatsu Photonics K.K., Mikroscan Technologies, Inc., Inspirata, Inc., Visiopharm A/S, and 3DHISTECH Ltd.
Recent strategies deployed in Digital Pathology Market
Partnerships, Collaborations, and Agreements:
Feb-2021: Leica Biosystems collaborated with Baylor College of Medicine. Under this collaboration, both the entities launched global pathology services. The creative solution by both the entities helped in developing enhanced latest approaches to diagnose and cure disease for providing a high quality of healthcare.
Oct-2020: Royal Philips collaborated with Singapore General Hospital (SGH). This collaboration aimed to set up the Singapore General Hospital Digital and Computational Pathology Center of Excellence. The SGH Center of Excellence focused on enhancing pathology practice by applying a fully digital histopathology workflow and implementing Artificial Intelligence (AI) to raise productivity and improve patient care.
Jun-2020: Royal Philips entered into a collaboration with Proscia, a leading provider of AI-enabled digital pathology solutions. In this collaboration, Proscia integrated the Philips Pathology SDK to primarily use Philips’ iSyntax image format with its Concentriq digital pathology platform and portfolio of AI modules, offering customers of Philips’ digital pathology solutions with expanded choices to fulfill their business and workflow requirements. Together, the companies aimed to advance an open ecosystem that can assist laboratories in boosting and scaling digital pathology adoption.
Apr-2020: Hamamatsu and KiKo Knowledge Hub collaborated with Inspirata, a cancer diagnostics solution. Under this collaboration, Hamamatsu and KiKo Knowledge Hub joined the initiative by Inspirata to deliver a Free Remote Pathology Solution for Healthcare Institutions affected by COVID-19. Hamamatsu offered its high-quality research use only (RUO) Whole Slide Image (WSI) scanner, NanoZoomer, to scan glass slides submitted by the organizations for research and secondary consults. This device cannot be utilized for any primary human diagnosis.
Mar-2020: Mikroscan signed a distribution agreement with Inspirata, a provider of cancer diagnostics solutions. Under this agreement, Inspirata markets and distributes Mikroscan’s digital pathology and telemicroscopy systems, the SL5 Dual-Mode Real-Time Telemicroscopy and Digital Pathology system, and the L5 Real-Time Telemicroscopy system, across the United States.
Mar-2020: Inspirata entered into a partnership with Augmentiqs, a leading provider of augmented reality (AR) in healthcare. The partnership focused on decreasing histology case turnaround times and offers a means for laboratories to take out maximum value from digitizing their processes. Together, the companies also aimed to launch an innovative new solution for doing casework in which the pathologist can use AR to picturize directly into the earlier microscope critical case information and case-sharing functionality developing in Inspirata’s Dynamyx digital pathology solution.
Mar-2020: Visiopharm signed a multi-year partnership agreement with Proscia, a leader in digital pathology image and workflow management. Together, the companies aimed to provide deeply integrated AI-enabled solutions that boost breakthroughs in translational research and advance precision medicine. Visiopharm and Proscia have set up a global reseller and support agreement to boost the delivery of these integrated capabilities to the market.
Dec-2019: Leica Biosystems came into collaboration with Sectra, a Swedish company active within medical technology. The companies collaborated for the integrated clinical digital pathology solution. The collaboration was focused on fulfilling the clinical requirements of enterprise-level customer users like clinical research organizations, academic medical centers, and large hospital networks.
Dec-2019: Royal Philips came into collaboration with Paige, a leader in computational pathology. The collaboration aimed to provide clinical-grade AI applications to pathology laboratories. These AI technologies focus on helping pathologists identify, quantify and characterize cancer in tissue samples and do it accurately with greater efficiency.
Dec-2019: Inspirata formed a partnership with Cirdan, laboratory information systems (LIS), and medical-imaging leader. The partnership aimed to make it easier for UK clinical laboratories to adopt and take advantage of digitizing their histopathology workflow, allowing them to cash in the opportunities for enhanced patient outcomes presented through innovations such as AI.
Sep-2019: Inspirata came into partnership with Ibex Medical Analytics. Under this partnership, the companies focused on delivering customers with the ability to use the IBEX Second Read system directly from within Inspirata’s digital pathology solution to decrease cancer case turnaround times and diminish diagnostic errors in high-throughput clinical laboratories.
May-2019: Royal Philips joined hands with Alverno Laboratories, the largest integrated laboratory network in the United States. Under this collaboration, Alverno implements digital pathology in its clinical laboratories. These laboratories network utilizes Philips IntelliSite Pathology Solution to evaluate and diagnose all clinical histology cases digitally, despite utilizing a microscope, with its focus on enhancing laboratory quality, efficiency, and patient safety.
Acquisition and Mergers:
Jan-2018: Inspirata acquired Pittsburgh-based Omnyx from GE Healthcare. The acquisition helped Inspirata to strengthen its position with a complete digital pathology workflow solution and expand its Digital Pathology Portfolio.
Dec-2016: Visiopharm took over LRI Imaging AB. Together, the companies become a highly specialized European leader in diagnostic digital pathology solutions.
Product Launches and Product Expansions:
Jan-2021: Roche introduced its automated digital pathology algorithms, uPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer. The image analysis algorithms utilize artificial intelligence to help pathologists in taking quick and more accurate patient diagnoses in breast cancer.
Dec-2020: 3DHISTECH unveiled New Clinical Pathology Product Line, PANNORAMIC Pathology Diagnostic System. This system is a new, combined digital pathology solution from 3DHISTECH that helps the pathologist to offer a faster diagnosis. PANNORAMIC is an all-in-one solution customized to the requirements of routine pathology laboratories, assist them to achieve higher throughput, lower turnaround times, and helping in faster diagnosis.
Aug-2020: Leica Biosystems launched its Aperio GT 450 DX digital pathology scanner in the European region. The scanner helps in delivering the best image quality and rapid scanning. This technology allowed laboratories to augment digital pathology for high-throughput, routine diagnostics.
Jun-2020: Roche launched its automated digital pathology platform, uPath PD-L1 (SP263) for non-small cell lung cancer (NSCLC). This platform utilizes AI technology to deliver pathologists with automated assessments of scanned slide images, which are coherent and can help in diagnosis and target treatment options for patients.
Mar-2020: Leica Biosystems introduced a substantial development for anatomical pathology laboratories by bringing together its Aperio AT2 DX System, digital pathology whole slide imaging along with Aperio Path DX web-based, state-of-the-art, case management software. By the continuous enhancements around the pathology workflow, Leica has implemented a complete clinical and operational expertise, which redefines efficiency.
Aug-2019: Leica Biosystems introduced the Aperio GT 450, its next-generation digital pathology scanner. This product provides a continuous rack loading with priority scanning and takes only 32 seconds to scan a 15mm by 15mm tissue area on a pathology slide at 40x magnification with the ability of 81 slides/hr.
Jan-2019: Roche introduced its new uPath enterprise software for digital pathology. This software enhances the early version, Ventana Virtuoso, with new tailored offerings for pathology workflows. uPath improves the customer experience by significantly reduce image rendering times, combining automated image analysis, and enhance efficiency by allowing an advanced workflow for sharing cases between pathologists.
Scope of the Study
Market Segments covered in the Report:
• Storage System
By End Use
• Diagnostic Labs
• Biotech & pharma companies
• Academic & research institutes
• Drug Discovery & Development
• Disease Diagnosis
• Academic research
• North America
o Rest of North America
o Rest of Europe
• Asia Pacific
o South Korea
o Rest of Asia Pacific
o Saudi Arabia
o South Africa
o Rest of LAMEA
• Danaher Corporation (Leica Biosystems)
• Koninklijke Philips N.V.
• Olympus Corporation
• F. Hoffmann-La Roche Ltd.
• ContextVision AB
• Hamamatsu Photonics K.K.
• Mikroscan Technologies, Inc.
• Inspirata, Inc.
• Visiopharm A/S
• 3DHISTECH Ltd.
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free